Miscibility studies of indomethacin and Eudragit® E PO by thermal, rheological, and spectroscopic analysis

Journal of Pharmaceutical Sciences

Volumn 101, Issue 6, 2012, Pages 2204-2212

  Liu, Huiju ^a   Zhang, Xueyan ^b   Suwardie, Herman ^c   Wang, Peng ^d   Gogos, Costas G ^a  

^a NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

^b NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

^c Polymer Processing Institute   (United States)

^d The University of Rhode Island   (United States)

Author keywords

Eudragit E PO; Glass transition; Indomethacin; Ionic interactions; Molecular interactions; Rheology; Solid dispersion; Spectroscopy; Stability; Thermal analysis

Indexed keywords

EUDRAGIT; INDOMETACIN; PLASTICIZER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; FLOW KINETICS; GLASS TRANSITION TEMPERATURE; INFRARED SPECTROSCOPY; MISCIBILITY; MOLECULAR INTERACTION; THERMAL ANALYSIS; VISCOSITY;

EID: 84862800151     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23075     Document Type: Article

References (35)

1. Chiou WL, Riegelman S. 1971. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 60:1281-1301.
2. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Sci 0:47-60.
3. Qian F, Huang J, Hussain MA. 2010. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci 9:2941-2947.
4. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharmaceut 5:1003-1019.
5. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, McGinity JW, Martin C. 2007. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Dev Ind Pharm 33:909-926.
6. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, Martin C, McGinity JW. 2007. Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev Ind Pharm 33:1043-1057.
7. Ivanisevic I. 2010. Physical stability studies of miscible amorphous solid dispersions. J Pharm Sci 99:4005-4012.
8. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
9. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization, and stabilization. Adv Drug Deliver Rev 48:27-42.
10. Yoo SU, Krill SL, Wang Z, Telang C. 2009. Miscibility/stability considerations in binary solid dispersion systems composed of functional excipients towards the design of multi-component amorphous systems. J Pharm Sci 98:4711-4723.
11. Zhu Y, Shah NH, Malick AW, Infeld MH, McGinity JW. 2006. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Drug Dev Ind Pharm 32:569-583.
12. Filippis PD, Boscolo M, Gibellini M, Rupena P, Rubessa F, Moneghini M. 1991. The release rate of indomethacin from solid dispersions with Eudragit® E. Drug Dev Ind Pharm 17:2017-2028.
13. Lin SY, Perng RI. 1993. Solid-state interaction studies of drugs/polymers I. Indomethacin/Eudragit® E, RL or S resins. S.T.P. Pharma Sci 3:465-471.
14. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H. 2005. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution. J Pharm Sci 94:2463-2474.
15. Chokshi RJ, Shah NH, Sandhu HK, Malick AW, Zia H. 2008. Stabilization of low transition temperature indomethacin formulations: Impact of polymer-type and its concentration. J Pharm Sci 97:2286-2298.
16. Liu H, Wang P, Zhang X, Shen F, Gogos CG. 2010. Effects of extrusion process parameters on the dissolution behavior of indomethacin in Eudragit® E PO solid dispersions. Int J Pharm 383:161-169.
17. Liu H. 2010. Hot melt mixing/extrusion and dissolution of drug (indomethacin) in acrylic copolymer matrices. Ph.D. Thesis. Newark, New Jersey: New Jersey Institute of Technology.
18. Forster A, Hempenstall J, Rades T. 2001. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol 53:303-315.
19. Forster A, Hempenstall J, Tucker I, Rades T. 2001. The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion. Drug Dev Ind Pharm 27:549-560.
20. Schneider HA. 1989. Glass transition behavior of compatible polymer blends. Polymer 30:771-779.
21. Tong P, Zografi G. 2001. A study of amorphous molecular dispersions of indomethacin and its sodium salt. J Pham Sci 90:1991-2004.
22. Lyons JG, Blackie P, Higginbotham CL. 2008. The significance of variation in extrusion speeds and temperatures on a PEO/PCL blend based matrix for oral drug delivery. Int J Pharm 351:201-208.
23. Paradkar A, Kelly A, Coates P, York P. 2009. Shear and extensional rheology of hydroxypropyl cellulose melt using capillary rheometry. J Pharmaceut Biomed 49:304-310.
24. Yang M, Wang P, Suwardie H, Gogos CG. 2011. Determination of acetaminophen's solubility in poly(ethylene oxide) by rheological, thermal and microscopic methods. Int J Pharm 403:83-89.
25. Suwardie H, Wang P, Todd DB, Panchal V, Yang M, Gogos CG. 2011. Rheological study of the mixture of acetaminophen and polyethylene oxide for hot-melt extrusion application. Eur J Pharm Sci 78:506-512.
26. Shenoy AV, Saini DR. 1996. Thermoplastic melt rheology and processing. New York: Marcel Dekker Inc., pp 85-87.
27. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14:1691-1698.
28. Kistenmacher TJ, Marsh RE. 1972. Crystal and molecular structure of an anti-inflammatory agent, indomethacin 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid. J Am Chem Soc 94:1340-1345.
29. Lin SY, Yu H, Li MJ. 1999. Formation of six-membered cyclic anhydrides by thermally induced intramolecular ester condensation in Eudragit® E film. Polymer 40:3589-3593.
30. Juppo AM, Boissier C, Khoo C. 2003. Evaluation of solid dispersion particles prepared with SEDS. Int J Pharm 250:385-401.
31. Menjoge AR, Kulkarni MG. 2007. Mechanistic investigations of phase behavior in Eudragit® E blends. Int J Pharm 343:106-121.
32. Weuts I, Kempen D, Verreck G, Peeters J, Brewster M, Blaton N, Van Den Mooter G. 2005. Salt formation in solid dispersions consisting of polyacrylic acid as a carrier and three basic model compounds resulting in very high glass transition temperatures and constant dissolution properties upon storage. Eur J Pharm Sci 25:387-393.
33. Moustafine RI, Zaharov IM, Kemenova VA. 2006. Physicochemical characterization and drug release properties of Eudragit® E PO/Eudragit® L 100-55 interpolyelectrolyte complexes. Eur J Pharm Biopharm 63:26-36.
34. Socrates G. 2001. Infrared and Raman characteristic group frequencies tables and charts. 3rd ed. West Sussex, England: John Wiley & Sons, Ltd., pp 107-114.
35. Evonik. 2007. Specifications and test methods for Eudragit® E 100, Eudragit® E PO and Eudragit® E 12.5.